This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

OmniAb Antibody Program

Gilead Sciences, Inc.

Drug Names(s): Monocolonal Antibody Program

Description: Gilead is discovering and developing fully mono- and bispecific antibodies for the treatment of various diseases using Ligand Pharmaceuticals' OmniAb platform.

Deal Structure: Gilead and Ligand
In July 2016, Ligand Pharmaceuticals announced it has entered into a worldwide license agreement with Gilead Sciences. Under the license, Gilead will be able to use the OmniRat, OmniMouse and OmniFlic platforms to discover fully human mono- and bispecific antibodies to be developed for the treatment of various diseases. Ligand is eligible to receive annual platform access payments, milestone payments and royalties for each product incorporating an OmniAb antibody. Gilead will be responsible for all costs related to the programs.

Partners: Ligand Pharmaceuticals, Inc.


OmniAb Antibody Program News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug